# EDGAR Filing Document

**Accession Number:** 0001584371
**File Stem:** 0001213900-26-034171
**Filing Date:** 2026-3
**Character Count:** 7635
**Document Hash:** 91a97c99e4dba605cb234faefd5ea582
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-034171.hdr.sgml**: 20260325

**ACCESSION NUMBER**: 0001213900-26-034171

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260325

**DATE AS OF CHANGE**: 20260325

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Mayron Ron
- **CENTRAL INDEX KEY:** 0001722033

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40753
- **FILM NUMBER:** 26793481

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 22A ORANIM ST
- **CITY:** HOD HASHARON
- **PROVINCE COUNTRY:** L3
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IceCure Medical Ltd.
- **CENTRAL INDEX KEY:** 0001584371
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7 HA'ESHEL ST., POB 3163
- **CITY:** CAESAREA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 38900
- **BUSINESS PHONE:** 972-4-6230333

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7 HA'ESHEL ST., POB 3163
- **CITY:** CAESAREA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 38900

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Mayron Ron<br><sub>(Last) (First) (Middle)</sub><br>7 HA'ESHEL ST., PO BOX 3163<br><sub>(Street)</sub><br>CAESAREA, ISRAEL 3079504<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>IceCure Medical Ltd. [ ICCM ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary shares | 296631<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Share option (right to buy) | <sup>(2)</sup> | 2028-01-10 | Ordinary shares | 95295 | 1.55<sup>(3)</sup> | D |  |
| Share option (right to buy) | <sup>(4)</sup> | 2029-05-21 | Ordinary shares | 25000 | 1.79<sup>(5)</sup> | D |  |
| Share option (right to buy) | <sup>(6)</sup> | 2030-10-28 | Ordinary shares | 25000 | 1.68<sup>(7)</sup> | D |  |
| Share option (right to buy) | <sup>(8)</sup> | 2032-01-12 | Ordinary shares | 110000 | 3.64<sup>(9)</sup> | D |  |
| Share option (right to buy) | <sup>(10)</sup> | 2033-02-19 | Ordinary shares | 59295 | 1.51<sup>(11)</sup> | D |  |

---

### Footnotes:

(1) Represents (i) 10,000 ordinary shares, and (ii) 286,631 restricted share units ("RSUs") granted on May 15, 2025, 25% of which vested on July 1, 2025 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, of which 107,486 RSUs have vested and 179,631 remain unvested as of March 18, 2026.

(2) The options were granted on January 10, 2018, and vested in equal quarterly installments of 6.25% beginning on December 5, 2017. As of March 18, 2026, all 95,295 options are fully vested.

(3) The options were granted with an exercise price of NIS 4.8 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.55 per share.

(4) The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning on May 21, 2019. As of March 18, 2026, all 25,000 options are fully vested.

(5) The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share.

(6) The options were granted on October 28, 2020, 25% of which vested on October 28, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 25,000 options are fully vested.

(7) The options were granted with an exercise price of NIS 5.2128 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.68 per share.

(8) The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 110,000 options are fully vested.

(9) The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.

(10) The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 44,471 options are vested.

(11) The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.

**Signature:** /s/ Ron Mayron  
**Date:** 2026-03-25

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**